Table 3. Multivariable analyses of prognostic factors for the entire study population.
| Variables | N (%) | 5-year OS (%) | HR | 95%CI | P value |
|---|---|---|---|---|---|
| pT stage | 0.841 | ||||
| pT1 | 41 (21.1) | 62.5 | 1.000 | – | – |
| pT2 | 58 (29.9) | 50 | 0.901 | 0.528–1.536 | 0.701 |
| pT3 | 50 (25.8) | 44 | 0.948 | 0.553–1.627 | 0.847 |
| pT4 | 45 (23.2) | 55.6 | 0.783 | 0.441–1.391 | 0.404 |
| pN stage | 0.003 | ||||
| pN0 | 75 (38.7) | 71.6 | 1.000 | – | – |
| pN1 | 42 (21.6) | 50 | 1.559 | 0.944–2.730 | 0.083 |
| pN2 | 41 (21.1) | 34.1 | 2.422 | 1.420–4.132 | 0.001 |
| pN3 | 36 (18.6) | 36.1 | 2.510 | 1.449–4.345 | 0.001 |
| Lymphadenectomy | 0.746 | ||||
| D2 | 100 (51.5) | 58.6 | 1.000 | – | – |
| D2+ | 61 (31.4) | 41 | 1.157 | 0.703–1.903 | 0.566 |
| D3 | 33 (17.0) | 54.5 | 1.229 | 0.707–2.134 | 0.465 |
| Reconstruction type | 0.011 | ||||
| Billroth I | 171 (88.1) | 57.1 | 1.000 | – | – |
| Billroth II | 21 (10.8) | 19 | 1.874 | 1.063–3.304 | 0.300 |
| Roux-Y | 2 (1.0) | 0 | 5.734 | 1.226–26.811 | 0.260 |
| Complications† | 0.021 | ||||
| Absent | 157 (80.9) | 53.8 | 1.000 | – | – |
| Present | 37 (19.1) | 45.9 | 1.725 | 1.085–2.740 | 0.021 |
| Lymphatic vessel invasion | 0.720 | ||||
| Negative | 82 (84.5) | 56.5 | 1.000 | – | – |
| Positive | 15 (15.5) | 35.9 | 1.102 | 0.649–1.868 | 0.720 |
| Locoregional recurrence | 0.318 | ||||
| Absent | 162 (83.5) | 52.5 | 1.000 | – | – |
| Present | 32 (16.5) | 51.6 | 1.323 | 0.764–2.293 | 0.318 |
| Distant metastasis | 0.996 | ||||
| Absent | 137 (70.6) | 52.6 | 1.000 | – | – |
| Present | 57 (29.4) | 51.8 | 0.999 | 0.628–1.588 | 0.996 |
†, including urinary infection/retention, delayed gastric emptying, intestinal obstruction/ileus, pneumonia, abdominal infection/abscess, wound infection/dehiscence, subphrenic infection/abscess, dumping syndrome, anastomotic fistula, postoperative hemorrhage, pancreatic fistula, and cholecystitis. EGA, epidural plus general anesthesia; GA, general anesthesia; HR, hazard ratio; CI, confidence intervals; OS, overall survival.